Navigation Links
Xenon Enters Cardiovascular Disease Collaboration With Merck & Co., Inc.
Date:6/11/2009

VANCOUVER, Canada, June 11 /PRNewswire/ -- Xenon today announced a strategic alliance with Merck & Co., Inc., through an affiliate, to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease.

"We are very excited to be collaborating with Merck to define new therapeutics in the area of cardiovascular diseases," said Simon Pimstone, President and CEO of Xenon. "With this deal, Xenon is continuing its strategy of risk mitigation by select partnering, while retaining ownership of other programs."

In collaboration with Merck, Xenon will perform validation studies using its clinical genetics platform, as well as drug discovery and select preclinical development of small molecule compounds for those targets selected by a joint steering committee.

Under the terms of the agreement, Merck has the option to exclusively license targets and compounds from Xenon for development and commercialization. In return, Xenon receives research funding and is eligible for option exercise fees, research, development and regulatory milestone payments of up to US$94.5million for the first target and up to US$89.5 million for each subsequent target selected for drug discovery. In addition, Merck will pay Xenon undisclosed royalties on sales of products resulting from the collaboration. Xenon retains the right to develop and commercialize certain compounds for which Merck does not exercise its option.

Michael Hayden, CSO of Xenon added, "We recognize that Merck is a leading pharmaceutical company with significant presence in and commitment to the cardiovascular space and they are an ideal strategic partner for Xenon. This new alliance, which represents our fifth partnership with a major pharmaceutical company, once again highlights Xenon's R&D capabilities and validates our drug discovery platform."

About Xenon Pharmaceuticals Inc. (Xenon)

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
2. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
3. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
4. Navitas Opens New Cancer Rehabilitation Center in Albuquerque in Conjunction With New Mexico Cancer Centers
5. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
6. Service-to-Sales Transformation at Contact Centers Hinges on Soft Skills
7. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
8. Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements
9. Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care
10. Pennsylvania Trauma Systems Foundation Accreditation Status for Trauma Centers
11. Vangent, Inc. Wins Spot on Centers for Medicare & Medicaid Services Enterprise System Development Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, ... of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular ... Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal of ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is ... X. Drag and drop a TransWipe preset between two video clips to instantly add ... wipes to colored panels with customizable color and orientation options. TransWipe Volume 3 is ...
(Date:5/5/2016)... ... 2016 , ... Qrono Inc. , a specialty pharmaceutical ... with the Australian critical medicine company, Phebra Pty Ltd. , to develop ... can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved adherence, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud ... cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which ... American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations ...
(Date:5/5/2016)... ... ... weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team ... Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Moeschler, who’ll share pro tips with the injured veterans as they rip down some of ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... Research and Markets has ... Market and Competitive Landscape Highlights - 2016" ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) The ... Landscape Highlights - 2016, provides comprehensive insights ... market valuations and forecast, Thalassaemia products sales ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... time for an upgrade. There are many medical recorders on the market but none ... DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller ... innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology: